AI-generated · cited to primary sources · not investment advice · How we research
Balaji Amines
Our verdict on Balaji Amines isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The Methyl Amines plant at Unit IV was successfully commissioned on 10 Nov 2024, reaching the target capacity of 88,000 TPA. (5 met across 5 tracked commitments)
“Iso Propyl Amine : The Company has undertaken modifications at the existing Ethyl Amines facility at Unit-I to enable the production of Iso Propyl Amines (MIPA/DIPA), with an estimated capacity of 20–21 MT/day. Commissioning of the plant is expected post-receipt of the Consent to Operate from the MPCB”
Consolidated EBITDA margin for Q1FY26 fell to 17%, missing the guided range of 19-20%. Standalone margins remained at 20%. (1 missed, 1 met, 1 exceeded across 3 tracked commitments)
“See, with a reasonable EBITDA, we should be in a position to maintain 20% to 22%.”
See the full cited Management analysis of Balaji Amines
How durable is the business?
The company is expanding its backward integration by commissioning a new solar power plant to reduce utility costs and upgrading plants to consume low-cost internal products for high-value output. (4 expanding)
“80% of our Methylamines production is captively used... will give a cost advantage over the competitors”
Specialty Chemicals volume expanded significantly from 10,660 MT to 11,889 MT, becoming the primary driver of volume growth and reinforcing its position as the largest segment. (1 expanding)
“Specialty Chemicals volumes stood at 11,889 MT”
See the full cited Business Model analysis of Balaji Amines
Where does growth come from?
The company is doubling its capacity for Acetonitrile using upgraded technology to improve cost efficiency and produce higher-quality grades for the pharma industry.
“Acetonitrile (ACN) Improved process based New ACN plant is under execution... expected to be commissioned during the Second Quarter of FY 2026-27.”
The subsidiary's expansion has been granted 'Mega Project' status by the Maharashtra government, involving a Rs. 750 crore investment. Environmental clearance has been cleared in the committee meeting, signaling steady progress toward import substitution. (3 steady, 1 new trend across 4 signals, 1 leading indicator)
“New expansion of Rs. 750 crs in Subsidiary Balaji Speciality Chemicals Limited... The proposed project is for manufacture of HCN, NaCN, EDTA and EDTA-2Na. The same are expected to be commissioned during the Q4 of FY 2026-27.”
See the full cited Future Growth analysis of Balaji Amines
What could break the thesis?
This risk remains stable as the pharmaceutical sector continues to provide the 'base volumes' and stable demand that offsets volatility in other segments like agrochemicals. (2 stable, 3 easing, 1 high-severity)
“Pharma 65% [Industry Wise - Revenue Breakup]”
Execution risk is intensifying as Capital Work-in-Progress (CWIP) has increased from Rs. 150 Cr to Rs. 173 Cr at the standalone level, and the company has added a massive Rs. 750 Cr expansion plan for its subsidiary. (2 intensifying, 3 easing, 1 high-severity)
“The capital work-in-progress across various units, totaling to RS. 187 crore... The capital work-in-progress at the subsidiary Balaji Speciality Chemicals Ltd (BSCL) amounts to Rs. 343 crore”
See the full cited Risk analysis of Balaji Amines
Read the full thesis on Balaji Amines
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.